Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19
VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has …